A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.

Abstract	Glioblastoma is the most malignant tumor and has high mortality rate. The methylated prompter of MGMT results in chemotherapy sensitivity for these patients. However, there are still other factors that affected the prognosis for the glioblastoma patients with similar MGMT methylation status. We developed a signature with three genes screened from the whole genome mRNA expression profile from Chinese Glioma Genome Atlas (CGGA) and RNAseq data from The Cancer Genome Atlas (TCGA). Patients with MGMT methylation in low risk group had longer survival than those in high risk group (median overall survival 1074 vs. 372 days; P = 0.0033). Moreover, the prognostic value of the signature was significant difference in cohorts stratified by MGMT methylation and chemotherapy (P=0.0473), while there is no significant difference between low and high risk group or unmethylated MGMT patients without chemotherapy. Multivariate analysis indicated that the risk score was an independent prognosis factor (P = 0.004). In conclusion, our results showed that the signature has prognostic value for patients with MGMT promoter-methylated glioblastomas based on bioinformatics analysis.
Authors	Wen Wang, Lu Zhang, Zheng Wang, Fan Yang, Haoyuan Wang, Tingyu Liang, Fan Wu, Qing Lan, Jiangfei Wang, Jizong Zhao
Journal	Oncotarget (Oncotarget) Vol. 7 Issue 43 Pg. 69991-69999 (Oct 25 2016) ISSN: 1949-2553 [Electronic] United States
PMID	27588397 (Publication Type: Journal Article)
Chemical References	Tumor Suppressor Proteins DNA Modification Methylases MGMT protein, human DNA Repair Enzymes
Topics	Adult Aged Brain Neoplasms (drug therapy, genetics, mortality) DNA Methylation DNA Modification Methylases (genetics) DNA Repair Enzymes (genetics) Female Glioblastoma (drug therapy, genetics, mortality) Humans Male Middle Aged Prognosis Promoter Regions, Genetic Proportional Hazards Models Tumor Suppressor Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!